Dyne Therapeutics Announces Proposed Public Offering of Common Stock
Dyne Therapeutics (NASDAQ: DYN), a clinical-stage company specializing in neuromuscular disease treatments, has announced a proposed public offering of $200 million of common stock shares. The company will also grant underwriters a 30-day option to purchase up to an additional $30 million in shares.
The offering will be managed by joint book-running managers Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities, with Jones acting as co-manager. The offering will be made through a shelf registration statement on Form S-3 previously filed with the SEC on March 5, 2024.
The completion of the offering is subject to market and other conditions, with final terms to be disclosed in a final prospectus supplement to be filed with the SEC.
Dyne Therapeutics (NASDAQ: DYN), un'azienda in fase clinica specializzata nel trattamento delle malattie neuromuscolari, ha annunciato un'offerta pubblica proposta di azioni ordinarie per un valore di 200 milioni di dollari. La società concederà inoltre agli underwriter un'opzione di 30 giorni per acquistare fino a un ulteriore 30 milioni di dollari in azioni.
L'offerta sarà gestita dai joint book-running manager Morgan Stanley, Jefferies, Stifel e Guggenheim Securities, con Jones come co-manager. L'offerta sarà effettuata tramite una dichiarazione di registrazione a scaffale sul modulo S-3, precedentemente depositata alla SEC il 5 marzo 2024.
Il completamento dell'offerta è soggetto a condizioni di mercato e altre condizioni, con i termini finali che saranno comunicati in un supplemento al prospetto finale da presentare alla SEC.
Dyne Therapeutics (NASDAQ: DYN), una empresa en etapa clínica especializada en tratamientos para enfermedades neuromusculares, ha anunciado una oferta pública propuesta de acciones comunes por un valor de 200 millones de dólares. La compañía también otorgará a los suscriptores una opción de 30 días para comprar hasta 30 millones de dólares adicionales en acciones.
La oferta será gestionada por los gestores conjuntos de libro Morgan Stanley, Jefferies, Stifel y Guggenheim Securities, con Jones actuando como co-gestor. La oferta se realizará a través de una declaración de registro en estantería en el Formulario S-3 presentada previamente ante la SEC el 5 de marzo de 2024.
La finalización de la oferta está sujeta a condiciones de mercado y otras, y los términos finales se darán a conocer en un suplemento final del prospecto que se presentará a la SEC.
Dyne Therapeutics (NASDAQ: DYN)는 신경근 질환 치료를 전문으로 하는 임상 단계 기업으로, 2억 달러 규모의 보통주 공개 제안을 발표했습니다. 회사는 또한 인수인에게 추가로 최대 3천만 달러 규모의 주식을 30일 동안 매수할 수 있는 옵션을 부여할 예정입니다.
이번 공모는 공동 주간사인 Morgan Stanley, Jefferies, Stifel, Guggenheim Securities가 관리하며, Jones가 공동 매니저로 참여합니다. 공모는 2024년 3월 5일 SEC에 제출된 Form S-3 서류를 통한 선반 등록 신고서를 통해 이루어집니다.
공모 완료는 시장 상황 및 기타 조건에 따라 달라지며, 최종 조건은 SEC에 제출될 최종 투자설명서 보충서에서 공개될 예정입니다.
Dyne Therapeutics (NASDAQ: DYN), une société en phase clinique spécialisée dans les traitements des maladies neuromusculaires, a annoncé une offre publique proposée de 200 millions de dollars d'actions ordinaires. La société accordera également aux souscripteurs une option de 30 jours pour acheter jusqu'à 30 millions de dollars supplémentaires d'actions.
L'offre sera gérée par les gestionnaires principaux conjoints Morgan Stanley, Jefferies, Stifel et Guggenheim Securities, Jones agissant en tant que co-gestionnaire. L'offre sera réalisée via une déclaration d'enregistrement sur étagère sur le formulaire S-3 déposée auprès de la SEC le 5 mars 2024.
La réalisation de l'offre est soumise aux conditions du marché et autres, les termes finaux seront divulgués dans un supplément final du prospectus qui sera déposé auprès de la SEC.
Dyne Therapeutics (NASDAQ: DYN), ein Unternehmen in der klinischen Phase, das auf die Behandlung neuromuskulärer Erkrankungen spezialisiert ist, hat ein geplantes öffentliches Angebot von Stammaktien im Wert von 200 Millionen US-Dollar angekündigt. Das Unternehmen gewährt den Underwritern zudem eine 30-tägige Option zum Kauf von bis zu weiteren 30 Millionen US-Dollar an Aktien.
Das Angebot wird von den Joint Book-Running Managern Morgan Stanley, Jefferies, Stifel und Guggenheim Securities verwaltet, wobei Jones als Co-Manager fungiert. Das Angebot erfolgt über eine Shelf-Registrierungserklärung auf Formular S-3, die zuvor am 5. März 2024 bei der SEC eingereicht wurde.
Der Abschluss des Angebots hängt von Markt- und anderen Bedingungen ab, wobei die endgültigen Bedingungen in einem endgültigen Prospektergänzungsblatt, das bei der SEC eingereicht wird, bekannt gegeben werden.
- Potential to raise up to $230 million in total capital if overallotment option is exercised
- Strong lineup of reputable investment banks as underwriters
- Potential dilution for existing shareholders
- Stock offering subject to market conditions and may not complete
Insights
Dyne Therapeutics' $200M stock offering will substantially strengthen its cash position for advancing neuromuscular disease therapies through clinical trials.
Dyne Therapeutics is pursuing a substantial
The company has engaged prominent investment banks including Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities as joint book-running managers, indicating strong institutional support for this capital raise. This financing comes at a critical time as the company advances its pipeline of therapeutic candidates for genetically driven neuromuscular conditions.
The offering's structure as a shelf registration that was previously filed in March 2024 suggests Dyne had anticipated the need for additional capital to fund clinical development. This capital infusion will likely extend the company's operational runway, providing the resources needed to advance clinical trials, expand research initiatives, and potentially reach key development milestones.
For clinical-stage biotechs, adequate capitalization is essential to navigate the lengthy and expensive drug development process. This offering demonstrates both management's ability to access capital markets and investor confidence in Dyne's scientific approach to addressing neuromuscular diseases. The successful completion of this offering will significantly strengthen Dyne's balance sheet as they work toward developing functional improvements for patients with genetically driven neuromuscular conditions.
WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has commenced an underwritten public offering of
Morgan Stanley, Jefferies, Stifel and Guggenheim Securities are acting as joint book-running managers for the offering. Jones is acting as co-manager for the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The proposed offering is being made pursuant to a shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (“SEC”) on March 5, 2024 and became automatically effective upon filing. This offering will be made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering is expected to be filed with the SEC and, if and when filed, copies of the preliminary prospectus supplement relating to the offering may be obtained for free by visiting the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus may also be obtained by contacting: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at prospectus@morganstanley.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements relating to the proposed underwritten public offering, the anticipated terms of the proposed offering, market and other conditions relating to the offering, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all and other factors discussed in the “Risk Factors” section of the preliminary prospectus supplement to be filed with the SEC, as well as the risks and uncertainties identified in Dyne’s filings with the SEC, including Dyne’s most recent Form 10-Q and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne’s views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne’s views as of any date subsequent to the date of this press release.
Contacts:
Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353
Media
Stacy Nartker
snartker@dyne-tx.com
781-317-1938
FAQ
How much is Dyne Therapeutics (DYN) planning to raise in its public offering?
Who are the underwriters for Dyne Therapeutics' stock offering?
When did Dyne Therapeutics file its shelf registration statement?
What is Dyne Therapeutics' business focus?
How can investors access the preliminary prospectus for DYN's offering?
